In the retatrutide Phase 2 trial, discontinuation due to adverse events ranged from 6% at 4 mg doses to 16% at 12 mg, compared with 0% for placebo [1]
Watch for signs of pancreatitis (severe stomach pain), gallbladder issues (upper right abdominal pain), dehydration from persistent vomiting or diarrhea, or allergic reactions (swelling, difficulty breathing)
optimized to yield up to 10mg of soluble GST tagged protein
Researchers observed reduced brain damage in animal stroke models given BPC-157, pointing toward possible cognitive benefits
MS1 and MS2 accuracy, and retention time window scans, were set to 0 allowing DIA-NN to perform their automatic inference using first run in the experiment (DIA-NN recommended MS1 mass accuracy setting: 12.7639 ppm)